05 2022
Gearing up for ASCO 2022 event! Meet Explicyte in ...
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American ...Read more
-
Spotlight on our in vivo advancesDevelopment and characterization of a novel anti-PD1 resistant sarcoma mouse model
-
Let’s start the Digital Spatial Profiling revolution together!NanoString GeoMx DSP, certified partner
-
Spotlight onadenosine-mediated suppression of dendritic cell function
-
Spotlight on Explicyte integrated histology platformin Nature Cancer!
-
Featured ModelOrthotopic Glioblastoma Mouse Model
-
Cytokine release as relevant surrogatefor the immune cell subset function assessment on an in vitro platform of IO
-
Integrated Histology For Quantitative Digital PathologyHistology Services
-
We test novel cancer immunotherapiesImmuno-oncology dedicated services
Preclinical services CRO for drug discovery
Explicyte Immuno-Oncology
We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.
Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4 monoclonal antibodies, anti PD1/PDL-1 antibody therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France, serving clients all around the world.